2nd firm agrees to temporary shutdown in outbreak

by Jay Lindsay
This photo provided Oct. 9, 2012, by the Minnesota Department of Health shows shows vials of the injectable steroid product made by New England Compounding Center implicated in a fungal meningitis outbreak that were being shipped to the Centers for Disease Control and Prevention in Atlanta from Minneapolis. About 17,700 single-dose vials of the steroid sent to 23 states have been recalled. The outbreak involves 10 states, including Minnesota. (AP Photo/Minnesota Department of Health)

(AP)—A Massachusetts company run by the same executives who operated a specialty pharmacy linked to a fatal meningitis outbreak has agreed to temporarily shut down for inspection by state and federal regulators.

Ameridose is located in Westborough, Mass. The Compounding Center, which produced a steroid linked to the outbreak, is in Framingham. Both firms are run by Barry Cadden and Greg Conigliaro.

Ameridose provides sterile medication in prefilled oral syringes to about 3,000 hospitals nationwide. It opened its doors in 2006, eight years after NECC opened.

The Massachusetts Department of Public Health says Ameridose agreed to the shutdown until inspections by and the U.S. are completed.

There is no recall of Ameridose products.

The outbreak has sickened 137 people in 10 states. Twelve have died.

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Mass. gov: Drug firm may have misled regulators

Oct 10, 2012

(AP)—Massachusetts Gov. Deval Patrick says the specialty pharmacy linked to a deadly meningitis outbreak may have misled regulators and done work beyond the scope of its state license.

US pharmacy linked to outbreak issues wide recall

Oct 07, 2012

(AP)—The pharmacy that distributed a steroid linked to an outbreak of fungal meningitis has issued a voluntary recall of all of its products, calling the move a precautionary measure.

Recommended for you

Boxed warnings are common in novel therapeutics

Aug 19, 2014

(HealthDay)—Boxed warnings are common on recent drug approvals, and many occur years after approval, according to a research letter published online Aug. 15 in JAMA Internal Medicine.

AstraZeneca says DOJ closes probe into drug trial

Aug 19, 2014

British drugmaker AstraZeneca says the U.S. Department of Justice has closed its investigation into a clinical trial of the company's blood thinner Brilinta, and plans no further action.

Perampanel for epilepsy: Still no proof of added benefit

Aug 19, 2014

The drug perampanel (trade name Fycompa) has been approved since July 2012 as adjunctive ("add-on") therapy for adults and children aged 12 years and older with epileptic fits (seizures). In a new early benefit assessment ...

User comments